Safety and Targeting of Anti-hk2 Antibody in mCRPC
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with
mCRPC.
This imaging study will be conducted to confirm the safety and estimate the mass amount of
antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In)
radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide
the dosimetric information crucial for Phase 1 therapy.